KUALA LUMPUR: Pharmaniaga Bhd’s net profit for the third quarter ended Sept 30, 2026 (Q3 FY26) surged 261 per cent to RM26.3 million from RM7.3 million a year earlier, as it recorded RM16.4 million tax benefits.
Profit before zakat and taxation (PBT) rose to RM13 million from RM10.4 million previously, supported by interest savings of RM3.2 million following the partial repayment of borrowings and continued operational efficiency efforts.
The group declared a dividend of 0.32 sen per share for the quarter.
For the nine months ended Sept 30, 2026 (9M FY26), Pharmaniaga’s net profit increased 72.1 per cent to RM70.2 million from RM40.8 million in the corresponding period last year.
Revenue grew 8.2 per cent to RM3.23 billion from RM2.99 billion, primarily driven by stronger demand in its concession segment.
PBT increased 22 per cent to RM77.2 million from RM63.3 million, with the group recording interest savings of RM17.4 million following the partial repayment of borrowings using proceeds from its regularisation plan.
Looking ahead, Pharmaniaga said the government’s 2027 budget for healthcare of RM47.7 billion would provide a supportive backdrop for the industry.
The group is also expanding its biopharmaceutical portfolio after securing National Pharmaceutical Regulatory Agency approval for EVnyx, an Enterovirus 71 vaccine, and ISENDA (liraglutide), its first generic glucagon-like peptide-1 product targeting Type 2 diabetes and weight management.
It plans to launch nine new pharmaceutical products in 2027, focusing on cardiovascular, oncology, anti-infectives and vaccines.
Meanwhile, the group expects the number of products under its Approved Product Purchase List concession to increase from about 850 to more than 1,200 within the concession period.
Pharmaniaga is also progressing with the equipping of four strategically located warehouses, with full operations targeted to commence in the first quarter of 2027.